Curia to purchase biopharma fill-finish organization

Curia, formerly known as Albany Molecular Research Inc. (AMRI), a contract development and manufacturing organization (CDMO) that had been chosen to support the development and manufacture of lipid excipients for the Pfizer-BioNTech Covid-19 vaccine, has entered into a definitive agreement to acquire Camarillo, CA-based Integrity Bio, Inc., a privately held formulation and fill-finish company.

In the biopharma industry, Integrity Bio is known to specialize in hard-to-formulate biologics and fill-finish of therapies in preclinical and clinical development. In a normal year, the organization formulates over 60 large molecules, such as proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form. The company also recently expanded its facilities to now feature a second fill-finish line that has more than doubled manufacturing capacity.

According to the involved parties, Integrity Bio’s biologic capabilities go hand-in-hand with Curia’s existing business and will enable Curia to expand its ability to meet customers’ needs. Curia offers customers with solutions from formulation development through fill-finish commercial manufacturing across three sites in Albuquerque, NM; Burlington, MA; and Glasgow, Scotland.

Although deal terms have not been disclosed, the transaction is anticipated to close in the third quarter.